Please login to the form below

Not currently logged in

GSK and MaRS launch innovation fund

GlaxoSmithKline and MaRS Innovation have set up a development fund that will support the commercialisation of translational research from 16 academic health science centres, hospitals and universities in Canada

GlaxoSmithKline (GSK) and MaRS Innovation (MI) – an organisation to help create successful global businesses from Canada's science, technology and social innovation - have set up a development fund that will support and fast-track the commercialisation of translational research coming from 16 academic health science centres, hospitals and universities in Canada.

The GSK/MI fund will support projects with strong potential for commercialisation in drug development, diagnostics and healthcare delivery technologies. The partnership will provide access to capitals and opportunities for early engagement with experts to guide and position technologies for successful commercialisation through licensing or start-up company creation.

Paul Lucas, president and chief executive of GSK Canada, said: "Collaborations such as these, where we share knowledge, expertise and resource, provide a highly effective way of progressing and commercialising cutting edge research. We hope that this collaboration will help close the innovation gap in Canada."

MI is a not-for-profit organisation funded through the Canadian government's Networks of Centres of Excellence and contributions from its member institutions.

1st June 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....